New York State Common Retirement Fund
MRSN

New York State Common Retirement Fund’s Mersana Therapeutics MRSN Stock Holding History

New York State Common Retirement Fund’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,489
Closed -$12.8K – 3285
2025
Q1 		$12.8K Hold
1,489
– – ﹤0.01% 3047
2024
Q4 		$53.2K Hold
1,489
– – ﹤0.01% 2840
2024
Q3 		$70.4K Hold
1,489
– – ﹤0.01% 2746
2024
Q2 		$74.8K Buy
1,489
+3
+0.2% +$217 ﹤0.01% 2981
2024
Q1 		$166K Sell
1,486
-4
-0.3% -$398 ﹤0.01% 2528
2023
Q4 		$86.4K Sell
1,490
-4
-0.3% -$161 ﹤0.01% 2810
2023
Q3 		$47.4K Buy
1,494
+14
+0.9% +$665 ﹤0.01% 3037
2023
Q2 		$122K Sell
1,480
-4
-0.3% -$585 ﹤0.01% 2704
2023
Q1 		$153K Sell
1,484
-755
-34% -$106K ﹤0.01% 2701
2022
Q4 		$328K Sell
2,239
-1
-0% -$169 ﹤0.01% 2519
2022
Q3 		$379K Buy
2,240
+292
+15% +$47.5K ﹤0.01% 2479
2022
Q2 		$225K Sell
1,948
-5
-0.3% -$470 ﹤0.01% 2744
2022
Q1 		$195K Sell
1,953
-119
-6% -$13.9K ﹤0.01% 2829
2021
Q4 		$322K Sell
2,072
-3
-0.1% -$584 ﹤0.01% 2672
2021
Q3 		$489K Sell
2,075
-303
-13% -$88.5K ﹤0.01% 2475
2021
Q2 		$807K Buy
2,378
+446
+23% +$169K ﹤0.01% 2331
2021
Q1 		$781K Hold
1,932
– – ﹤0.01% 2232
2020
Q4 		$1.28M Buy
1,932
+252
+15% +$140K ﹤0.01% 1919
2020
Q3 		$782K Hold
1,680
– – ﹤0.01% 2021
2020
Q2 		$983K Buy
1,680
+608
+57% +$208K ﹤0.01% 1880
2020
Q1 		$156K Buy
1,072
+604
+129% +$106K ﹤0.01% 2580
2019
Q4 		$67K Hold
468
– – ﹤0.01% 3090
2019
Q3 		$18K Sell
468
-1,000
-68% -$72.7K ﹤0.01% 3202
2019
Q2 		$149K Buy
1,468
+984
+203% +$116K ﹤0.01% 2954
2019
Q1 		$64K Hold
484
– – ﹤0.01% 3040
2018
Q4 		$49K Hold
484
– – ﹤0.01% 3092
2018
Q3 		$121K Hold
484
– – ﹤0.01% 3009
2018
Q2 		$216K Hold
484
– – ﹤0.01% 2836
2018
Q1 		$191K Buy
484
+352
+267% +$139K ﹤0.01% 2754
2017
Q4 		$54K Buy
132
+92
+230% +$40.1K ﹤0.01% 3039
2017
Q3 		$17K Buy
+40
New +$15.8K ﹤0.01% 3082

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

New York State Common Retirement Fund's MRSN Position: Q2 2025 in Review

New York State Common Retirement Fund sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 1,489 shares — an estimated $12.8K sold.

New York State Common Retirement Fund first reported a position in MRSN in Q3 2017 and held it in 31 quarters. The position peaked at $1.28M in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • New York State Common Retirement Fund reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • New York State Common Retirement Fund sold 1,489 Mersana Therapeutics shares in Q2 2025, an estimated $12.8K.
  • New York State Common Retirement Fund first reported a position in Mersana Therapeutics in Q3 2017 and held it in 31 quarters.
  • New York State Common Retirement Fund's Mersana Therapeutics position peaked at $1.28M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on New York State Common Retirement Fund's 13F filing for Q2 2025, filed 13 Aug 2025.